Mycophenolate Mofetil · Regulatory label update

FDA supplemental approval: Mycophenolate Mofetil (REMS)

U.S. Food and Drug Administration · July 29, 2026

Regulatory Update Why this matters to you Expert discussion

An action by a regulator. Authoritative on labelling and availability.

AI Summary

The FDA approved a supplemental application (REMS) for mycophenolate mofetil 250 mg capsules on 29 July 2026. This regulatory action establishes a Risk Evaluation and Mitigation Strategy but does not report clinical trial results, efficacy data, or comparative benefit.

What was studied

Regulatory label update.

Key findings

Supplemental approval granted for mycophenolate mofetil 250 mg oral capsule formulation REMS (Risk Evaluation and Mitigation Strategy) requirement imposed as condition of approval

Safety

No safety or efficacy comparison with other formulations or agents is provided.

Who this may help

This action does not provide evidence of clinical efficacy or comparative benefit. Clinicians should consult the approved labelling and REMS requirements to understand risk mitigation obligations, but this approval record does not inform treatment decisions based on clinical outcomes.

Plain-language summary

This is an FDA supplemental approval action establishing a Risk Evaluation and Mitigation Strategy (REMS) for mycophenolate mofetil; it does not report clinical trial outcomes or comparative efficacy.

Reported figures

Quoted from the source exactly as published.

Approval date2026-07-29

Dose and formulation250 mg capsule, oral

Clinical bottom line

Caveats

This record does not contain clinical trial results or efficacy data.
REMS strategy details are not specified in this approval summary.
No safety or efficacy comparison with other formulations or agents is provided.
The record does not state the indication or patient population affected by this approval.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

insufficient

Regulatory action record, not a clinical study design.

Directness

insufficient

Record does not report clinical outcomes or direct patient benefit evidence.

Consistency

insufficient

Single regulatory action; no comparative or replicated data presented.

Risk of bias

insufficient

Not applicable; this is a regulatory action, not a trial.

Sample adequacy

insufficient

No patient population or sample size reported in approval record.

Source abstract

Drugs@FDA record for application ANDA090055. This is a regulatory action record, not a clinical study. Brand name: MYCOPHENOLATE MOFETIL. Active ingredient: MYCOPHENOLATE MOFETIL. Sponsor: STRIDES PHARMA. Submission type: SUPPL (supplement). Submission class: REMS. Approval status date: 2026-07-29. Products: MYCOPHENOLATE MOFETIL, CAPSULE, ORAL, MYCOPHENOLATE MOFETIL 250MG.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

Mycophenolate MofetilStrides Pharma